GC241 Reference (3) - Patel Dementia With Lewy Bodies
Dementia with Lewy bodies is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, fluctuating attention, and parkinsonism due to abnormal alpha-synuclein protein deposits (Lewy bodies) in cortical and subcortical neurons.
Dementia with Lewy Bodies (DLB) — Comprehensive Exam-Ready Notes
This reference article (Patel, Continuum 2025) is a detailed review of Dementia with Lewy Bodies (DLB), covering its diagnostic criteria, prodromal syndromes, biomarkers, copathology, genetics, and management. It was assigned as reading material alongside the GC 241 dementia lecture, meaning examiners may draw questions from its content.
Why this matters clinically: DLB is the second most common neurodegenerative dementia after Alzheimer disease (AD), yet two out of three cases are missed or misdiagnosed as AD [1]. Misdiagnosis is dangerous because patients with DLB have severe sensitivity to antipsychotics — giving a typical antipsychotic to a DLB patient can cause acute irreversible parkinsonism, loss of consciousness, or neuroleptic malignant syndrome [1][2]. Getting the diagnosis right changes everything: which drugs you give, which drugs you avoid, and how you counsel families.
Core Concepts and Mechanisms (From First Principles)
α-Synuclein is a presynaptic protein that, when misfolded, aggregates into Lewy bodies and Lewy neurites — the pathological hallmark of all Lewy body diseases. [1]
- Normal α-synuclein sits at presynaptic terminals and helps with vesicle trafficking
- When it misfolds, it templates other α-synuclein molecules to misfold too (prion-like "seeding")
- These aggregates deposit in neurons → neuronal dysfunction → cell death
- The anatomical distribution of Lewy bodies determines the clinical phenotype:
- Brainstem predominant → motor parkinsonism (classic PD)
- Limbic/transitional → early neuropsychiatric features
- Neocortical → prominent cognitive decline (DLB)
- Amygdala predominant → may present with psychiatric symptoms
- Olfactory bulb only → incidental finding, may represent pre-clinical disease
The term "Lewy body dementia" (LBD) encompasses both DLB and Parkinson disease dementia (PDD). "Lewy body disease" is the pathologic term for neuronal α-synuclein aggregates found at autopsy. [1]
In DLB, the cholinergic deficit is actually more severe than in AD (loss of cholinergic neurons in the nucleus basalis of Meynert + loss of cortical acetylcholine), which paradoxically means cholinesterase inhibitors may work better in DLB than in AD. The dopaminergic deficit (substantia nigra degeneration) explains the parkinsonism and also underlies the visual hallucinations (disrupted dopaminergic modulation of visual processing in the occipital cortex and ventral visual stream).
The cognitive profile in DLB reflects frontosubcortical and posterior cortical dysfunction:
- Executive dysfunction → frontal circuits
- Attentional fluctuations → ascending reticular activating system + thalamic-cortical circuits
- Visuospatial deficits → occipitoparietal pathways
- Relative preservation of memory early on → hippocampus is relatively spared (unless AD copathology exists)
| Term | Definition | Exam Relevance |
|---|---|---|
| DLB | Cognitive dysfunction occurs before or within 1 year of parkinsonian motor symptoms | The "1-year rule" — know this cold |
| PDD | Cognitive dysfunction occurs after > 1 year from onset of parkinsonian motor symptoms | Reverse of DLB timing |
| LBD | Umbrella term encompassing both DLB and PDD | Don't confuse with "Lewy body disease" |
| Lewy body disease | Pathologic term — neuronal α-synuclein aggregates at autopsy | Used only in pathology context |
| MCI due to Lewy bodies | Prodromal DLB: cognitive difficulty in attention/executive/visuospatial but functionally independent | Doesn't meet dementia criteria |
| Delirium-onset DLB | Prodromal DLB where delirium occurs before dementia | Avoid antipsychotics! |
| Psychiatric-onset DLB | Prodromal DLB with late-onset depression or psychosis before dementia | May be misdiagnosed as primary psychiatric disorder |
Diagnostic Criteria for DLB (2017 Fourth Consensus Report)
Progressive cognitive decline interfering with normal social or occupational function, with prominent and early deficits in attention, executive function, and visuoperceptual processing. [1]
Note: Memory impairment may NOT be prominent early — this is a key differentiator from AD where episodic memory loss is the cardinal early feature.
| Feature | Details | Frequency |
|---|---|---|
| Fluctuating cognition | Pronounced variations in attention and alertness; care partners report "good days and bad days," staring blankly, losing train of thought | 60-80% [2] |
| Recurrent visual hallucinations | Well-formed and detailed — often people, children, animals; may also have passage hallucinations, visual illusions, presence hallucinations | Up to 80% [1] |
| REM sleep behaviour disorder (RBD) | Dream enactment: talking, yelling, punching, flailing during REM sleep; may precede other symptoms by years | 85% [2] |
| Parkinsonism | One or more of: bradykinesia, rest tremor, rigidity; usually bilaterally symmetric and milder than in PD | 70-90% [2] |
Fluctuations vs Delirium
A common exam trap: cognitive fluctuations in DLB can look like delirium. The difference is that DLB fluctuations are chronic, recurrent, without a clear precipitant, and occur in the context of progressive cognitive decline. In delirium, there is usually an identifiable acute cause (infection, medication, metabolic derangement). However, delirium can also be a prodromal presentation of DLB (delirium-onset DLB), so always think about underlying DLB if delirium has no clear trigger or is prolonged/recurrent. [1][4]
| Type | Description |
|---|---|
| Well-formed hallucination | Children, animals, insects, people (familiar or unfamiliar, dead or alive), inanimate objects |
| Passage hallucination | Shadow of something or someone passing quickly in peripheral visual field |
| Visual illusion | Physical object misperceived as something else (e.g., garden hose seen as a snake) |
| Presence hallucination | Feeling that someone is nearby or has just left the room |
| Capgras syndrome | Delusion that a familiar person has been replaced by an identical imposter |
Severe sensitivity to antipsychotics, hypersomnia, postural instability, hyposmia, repeated falls, hallucinations in other modalities, syncope or other transient episodes of unresponsiveness, systematized delusions, severe autonomic dysfunction, apathy, anxiety, and depression. [1]
| Level | Criteria |
|---|---|
| Probable DLB | ≥2 core clinical features, OR 1 core clinical feature + 1 indicative biomarker |
| Possible DLB | 1 core clinical feature alone, OR 1 indicative biomarker alone |
Diagnostic Tools and Approach
Cognitive assessment should include a screening tool assessing executive function, attention, and visuoperceptual/spatial processing — such as the MoCA. [1]
- MoCA is preferred over MMSE because MoCA specifically tests executive function (trails, clock drawing), attention (serial 7s, digit span), and visuospatial skills (cube copy) — all affected early in DLB
- Neuropsychological battery should include:
- Executive function/attention: trail-making tests, Stroop task, phonemic fluency, Wisconsin Card Sorting Test
- Visuospatial: figure copy (intersecting pentagons, complex figures), line orientation, pareidolia test
- The pareidolia test evokes visual hallucination-like illusions from ambiguous visual scenes — specific to DLB assessment [1]
Memory and naming are NOT typically affected early unless there is AD copathology [1].
Biomarkers
| Biomarker | What It Shows | Key Details |
|---|---|---|
| Dopamine transporter SPECT/PET (DaT scan) | Reduced dopamine transporter uptake in basal ganglia | Sensitivity 80%, specificity 92% vs AD; most helpful for distinguishing DLB from AD [1] |
| MIBG myocardial scintigraphy | Reduced cardiac sympathetic innervation (low uptake) | Sensitivity 69%, specificity 87% vs AD; not available in many countries [1] |
| Polysomnography | REM sleep without atonia | Presence of RBD with PSG confirmation + dementia with appropriate cognitive profile = sufficient for probable DLB [1] |
DaT Scan Caveat — High Yield
Reduced dopamine transporter uptake is NOT specific to DLB — it occurs in PD, MSA, PSP, CBD, and some frontotemporal dementias. The DaT scan is most useful when the clinical question is "Is this AD or DLB?" — it does NOT distinguish between different parkinsonian syndromes. [1]
| Biomarker | Finding |
|---|---|
| CT/MRI | Relative preservation of medial temporal lobe structures (cf. AD where hippocampal atrophy is prominent) |
| FDG-PET | Occipital hypometabolism with posterior cingulate island sign (preserved posterior cingulate metabolism relative to cuneus/precuneus — opposite of AD pattern) |
| EEG | Posterior slow-wave activity < 8 Hz (~90% of DLB vs ~10% of AD) |
| Test | Details |
|---|---|
| α-Synuclein skin biopsy | Detects phosphorylated α-synuclein in cutaneous nerve fibers; sensitivity > 92% for synucleinopathies; punch biopsies from posterior cervical, posterior thigh, posterior distal leg |
| CSF α-synuclein seed amplification assay (SAA) | Detects α-synuclein across LBD spectrum; sensitivity 59-95%, specificity 83-98%; highest sensitivity in neocortical (97-100%) and limbic (96%) LBD; lowest in amygdala-predominant (43-50%) and brainstem-predominant (17-50%) |
There are no plasma biomarkers available that reliably detect α-synuclein [1]. This is a potential MCQ discriminator.
Prodromal DLB Syndromes
Three prodromal DLB syndromes have been proposed: (1) MCI, (2) delirium onset, and (3) psychiatric onset. [1]
- Cognitive profile: Impaired attention, executive dysfunction, visual processing deficits with relatively preserved memory
- Functionally independent → does not meet criteria for dementia
- Core clinical features same as DLB criteria (fluctuations, VH, RBD, parkinsonism)
- Nonamnestic MCI is associated with progression to DLB [1]
Diagnostic certainty:
- Probable MCI-LB: ≥2 core clinical features (± biomarkers), OR 1 core feature + ≥1 biomarker
- Possible MCI-LB: 1 core feature without biomarker, OR ≥1 biomarker without core features
Suspect when: provoking factors for delirium are NOT identified, delirium is prolonged or recurrent, and the patient later develops progressive cognitive decline. [1]
- Core clinical features have limited diagnostic value in this setting because fluctuations and visual hallucinations can occur in any delirium, and parkinsonism may be drug-induced from antipsychotics used to treat the delirium
- Delirium occurs more frequently in individuals later diagnosed with DLB compared to AD (25% vs 7%) [1]
- Management: Avoid or minimize antipsychotics and anticholinergic medications [1]
- Presents with late-onset major depressive disorder or psychosis (visual hallucinations, Capgras syndrome, other delusions)
- Challenging to differentiate from primary late-onset psychosis
- Core features may be confounded: RBD can be caused by antidepressants, parkinsonism can be caused by antipsychotics, psychomotor slowing can be from depression
- Management: Avoid or minimize antipsychotics and anticholinergics [1]
Why Prodromal Recognition Matters
Recognizing prodromal DLB prevents iatrogenic harm (avoiding antipsychotics), guides families to seek appropriate resources (advance care planning, caregiver support), and may allow future disease-modifying interventions. [1]
Copathology with Alzheimer disease is observed in at least 50% of individuals with DLB and is associated with greater cognitive decline, greater risk of institutionalization, and mortality. [1]
| Copathology | Clinical Impact |
|---|---|
| Amyloid beta plaques + neurofibrillary tangles | Most common; leads to more memory changes and faster disease progression |
| TDP-43 | May reduce likelihood of receiving a clinical DLB diagnosis (masks the phenotype) |
| Cerebrovascular changes | Additive vascular cognitive impairment |
| Tau | Influences both cognitive and motor prognosis |
Key exam point: When a patient with suspected DLB has prominent amnestic changes (memory loss early and severe), suspect AD copathology. Case 2-3 in the reference perfectly illustrates this — a patient with both visuospatial/executive deficits AND severe memory impairment, whose autopsy confirmed both severe Lewy body pathology and intermediate AD neuropathologic changes [1].
Most cases of DLB are sporadic; however, identified genetic variations include GBA, SNCA, APOE, BIN1, TMEM175, and TPCN1. [1]
| Gene | Significance |
|---|---|
| GBA | Most important; mutations increase risk for LBD with or without AD pathology |
| SNCA | Codes for α-synuclein; familial forms a/w duplication/triplication [2] |
| APOE ε4 | Shared risk with AD; associated with severity of Lewy body pathology independent of AD pathology |
Treatment
No Disease-Modifying Therapy
There are currently no disease-modifying therapies for DLB. All treatment is symptomatic. Anti-amyloid therapies (lecanemab, donanemab) approved for early AD are NOT indicated for DLB — DLB is outside the appropriate use criteria. [1]
At each visit, review all medications and over-the-counter drugs. Medications that can worsen DLB symptoms include: anticholinergics (e.g., diphenhydramine for sleep, oxybutynin for urinary frequency), benzodiazepines, tricyclic antidepressants, and antipsychotics. [1]
Management by Symptom Domain
| Drug | Details |
|---|---|
| Donepezil | 5-10 mg daily (morning); SE: bradycardia, GI upset, insomnia, vivid dreams |
| Rivastigmine | Oral 1.5-6 mg BID or transdermal 4.6-13.3 mg/day; transdermal has fewer GI side effects |
| Galantamine | 4-12 mg BID; limited evidence (one open-label trial only) |
| Memantine | Mixed results in DLB; may be used as monotherapy or combined with AChEI |
Cholinesterase inhibitors may also improve neuropsychiatric symptoms in DLB. In some patients, AChEIs can worsen tremor — counsel about this. [1]
Step 1: Nonpharmacologic strategies first — caregiver education, environmental changes, communication strategies, behavioural approaches [1]
Step 2: Cholinesterase inhibitors or memantine may improve psychosis [1]
Step 3: If distressing psychosis persists or safety issues arise:
| Drug | Details | Special Considerations |
|---|---|---|
| Quetiapine | 25-150 mg; lower D1/D2 binding | Can initiate immediately; QT prolongation risk |
| Clozapine | 6.25-50 mg; lowest D2 binding | Requires baseline CBC + regular monitoring for agranulocytosis |
| Pimavanserin | 34 mg; 5-HT2A inverse agonist | FDA approved for PD psychosis only, not DLB; used off-label |
All antipsychotics carry a boxed warning for increased risk of death in dementia-related psychosis. [1]
Antipsychotic Sensitivity — Critical Safety Point
30-50% of DLB patients have severe sensitivity to antipsychotics, which can cause acute irreversible parkinsonism, loss of consciousness, or neuroleptic malignant syndrome. If you must use an antipsychotic, quetiapine or clozapine are preferred because of their lower D2 receptor binding affinity. NEVER use typical antipsychotics (haloperidol) in suspected DLB. [1][2]
Non-pharmacologic (always first):
- Remove furniture with sharp edges near the bed, pad corners, lower the mattress, use padded flooring [1]
- Review medications that may worsen RBD
Pharmacologic:
Levodopa monotherapy is used because other dopaminergic therapies have the potential to worsen nonmotor symptoms (eg, hallucinations, orthostatic hypotension). [1]
- Carbidopa/levodopa 25/100 mg TID, titrated as needed [1]
- Motor response tends to be less robust than in PD [1]
- ~1/3 of DLB patients treated with levodopa may experience worsening hallucinations or psychosis — counsel about this [1]
- Zonisamide (25-50 mg/day) is an adjunct option for parkinsonism in DLB [1]
- Mood disorders (depression, anxiety, apathy)
- Orthostatic hypotension
- Constipation
- Sialorrhea
- Urinary dysfunction
- Erectile dysfunction
- No pharmacologic treatments improve cognitive fluctuations [1]
| Symptom | First-Line | Notes |
|---|---|---|
| Cognition | AChEI (donepezil, rivastigmine) | May also help neuropsychiatric symptoms |
| Psychosis | Nonpharmacologic → AChEI → quetiapine/clozapine | Avoid typical antipsychotics |
| RBD | Bedroom safety → melatonin → clonazepam | Review offending medications |
| Parkinsonism | Carbidopa/levodopa monotherapy | Less effective than in PD |
| Fluctuations | No proven pharmacologic treatment | Some experts try AChEIs |
DLB progresses faster than Alzheimer disease, with survival of approximately 5-8 years from symptom onset. [1]
| Cause of Death | Frequency |
|---|---|
| Failure to thrive | 65% |
| Pneumonia and swallowing difficulties | 23% |
| Other medical conditions | 19% |
| Complications from a fall | 10% |
Counsel patients and families about expected disease trajectory. Provide timely referral to palliative care or hospice. Discuss advance care planning early [1].
Two out of three DLB cases are missed or misdiagnosed as AD; average time to diagnosis is ~18 months from symptom onset. 50% of patients saw > 3 doctors for > 10 visits over 1 year before receiving a DLB diagnosis. [1]
- DLB diagnoses were primarily made by neurologists (62%) vs primary care (6%)
- Women with DLB may experience diagnostic delay due to milder parkinsonism and lower rates of RBD
- Racial and ethnic minorities have lower rates of clinical DLB diagnosis despite similar pathological findings at autopsy [1]
| Feature | DLB | AD | PDD |
|---|---|---|---|
| Core cognitive deficit | Attention, executive, visuospatial | Episodic memory | Similar to DLB |
| Visual hallucinations | Early, prominent | Late or absent | Present but usually later |
| Cognitive fluctuations | Characteristic | Uncommon | Present |
| RBD | Very common, may precede | Rare | Common |
| Parkinsonism | Within 1 year of dementia | Absent or very late | Precedes dementia by > 1 year |
| Medial temporal lobe on MRI | Preserved | Atrophied | Variable |
| FDG-PET | Occipital hypometabolism, cingulate island sign | Temporoparietal hypometabolism | Similar to DLB |
| DaT scan | Abnormal | Normal | Abnormal |
| Antipsychotic sensitivity | Severe (30-50%) | Minimal | Present but less dramatic |
| Cholinergic deficit | Severe | Moderate | Severe |
| Prognosis | 5-8 years | 8-12 years | Variable, often shorter than PD alone |
Common Traps and Discriminators
-
"Memory loss" as presenting complaint in DLB: Care partners often report memory changes, but formal testing reveals the primary deficits are in attention, executive function, and visuospatial processing. If memory is truly severely impaired early, suspect AD copathology [1].
-
Fluctuations ≠ delirium: Both feature variable alertness, but DLB fluctuations are chronic without an identifiable acute cause.
-
DaT scan specificity trap: An abnormal DaT scan distinguishes DLB from AD but does NOT distinguish DLB from PD, MSA, PSP, or CBD [1].
-
RBD preceding DLB by years: RBD can present decades before cognitive symptoms. If a patient has isolated RBD, they are at high risk of developing a synucleinopathy [1].
-
Antipsychotic risk: If a question stem describes acute deterioration (severe parkinsonism, obtundation) after starting haloperidol in a demented patient → think DLB with antipsychotic sensitivity [1][2].
-
Levodopa in DLB: Less effective than in PD, and ~1/3 may develop worsened hallucinations. Still the treatment of choice for parkinsonism in DLB — just start low and go slow [1].
-
APOE gene and AD risk: The 2025 MCQ Q20 asks about the most common gene contributing to AD risk → APOE [6]. Note that APOE ε4 is also associated with severity of Lewy body pathology [1].
- GC 241 "A short course of dementia" covers the broad differential of dementia; DLB is positioned as the second most common neurodegenerative cause [1]
- GC 091 / Neurology movement disorders lecture: Parkinsonism features (TRAP), Hoehn & Yahr staging, Lewy bodies as inclusions in PD — the same pathology underlying DLB [9]
- GC 169 "My grandmother keeps forgetting things": Covers general approach to dementia in the elderly, including differentiation of DLB from AD and vascular dementia
- Seminar 4 Psychogeriatrics (Dr Cheng): Specifically notes that fluctuations in awareness/alertness should raise suspicion for delirium OR dementia with Lewy bodies [4]
- Ryan Ho Neurology/Psychiatry notes: Summarize DLB core features, demographics (onset ~75y, M:F = 4:1), antipsychotic sensitivity (30-50%), and key diagnostic imaging findings [2][5]
- Maksim Medicine Notes: Concise summary confirming the 1-year rule, treatment approach (AChEI for dementia, quetiapine/clozapine for psychosis, levodopa for parkinsonism, melatonin/clonazepam for RBD) [3]
High Yield Summary
- DLB = second most common neurodegenerative dementia.
- Core features: (1) Fluctuating cognition, (2) Recurrent well-formed visual hallucinations, (3) REM sleep behaviour disorder, (4) Parkinsonism. The 1-year rule distinguishes DLB from PDD. Cognitive profile emphasizes attention, executive, and visuospatial deficits with relatively preserved memory early on. Indicative biomarkers: DaT scan (reduced uptake), MIBG (low uptake), PSG (REM without atonia). MRI shows preserved medial temporal lobes (cf. AD). FDG-PET shows occipital hypometabolism with cingulate island sign. Management: AChEI for cognition, nonpharmacologic first then quetiapine/clozapine for psychosis (NEVER typical antipsychotics — 30-50% have severe sensitivity), melatonin then clonazepam for RBD, levodopa monotherapy for parkinsonism. AD copathology occurs in ≥50% and worsens prognosis. Survival 5-8 years; most common cause of death is failure to thrive. No disease-modifying therapy exists. Three prodromal syndromes: MCI, delirium-onset, psychiatric-onset.
Active Recall - Dementia with Lewy Bodies
[1] Lecture slides: GC 241. Reference (3) - Patel dementia with lewy bodies.pdf [2] Senior notes: Ryan Ho Neurology.pdf (Section 5.4.5 Dementia with Lewy Bodies; Section 5.4.1 Approach to Dementia) [3] Senior notes: Maksim Medicine Notes.pdf (Parkinson-plus syndromes / DLB section) [4] Lecture slides: Seminar 4 - Assessment for Psychogeriatrics - Dr CPW Cheng.pdf [5] Senior notes: Ryan Ho Psychiatry.pdf (Section 4.2.5 Dementia with Lewy Bodies) [6] Past papers: 2025 Fourth Summative MCQ.pdf (Q20) [9] Lecture slides: Neurology - Two cases of movement disorders.pdf
GC241 Reference (2) - New Vascular Neurocognitive Disorder Criteria JAMA
The 2023 JAMA consensus criteria provide an updated diagnostic framework for vascular cognitive impairment, integrating neuroimaging biomarkers of cerebrovascular disease with cognitive assessment to classify vascular contributions to cognitive impairment and dementia.
CFB PSY04 Aetiology Of Psychiatric Disorders
The aetiology of psychiatric disorders encompasses the interplay of genetic, neurobiological, psychological, and sociocultural factors that contribute to the development and manifestation of mental illness.